Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atibuclimab (IC14) for Treatment of ST-Elevation Myocardial Infarction
NCT06678074Phase 2Active, not recruiting
- Sponsor
- Implicit Bioscience
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atibuclimab in ST elevation myocardial infarction (STEMI), sponsored by Implicit Bioscience. Started Feb 2025; status: active, not recruiting.
02
Drugs
atibuclimab
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06678074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678074.